in vitro assays

Broad Capabilities. Boutique Services. Every program deserves a partner, not just a provider. We built Bio Duro to be exactly the right size: broad enough to support your science at every stage, agile enough to move when you need to move, and focused enough to treat your program like the priority it is. Explore Our Capabilities All Company News October 1, 2026 June 6, 2026 May 28, 2026 April 28, 2026 April 23, 2026 March 12, 2026 March 3, 2026 February 10, 2026 January 27, 2026 November 18, 2025 August 20, 2025 July 30, 2025 June 10, 2025 May 8, 2025 April 7, 2025 March 25, 2025 March 5, 2025 January 20, 2025 January 9, 2025 January 6, 2025 October 24, 2024 October 1, 2024 September 16, 2024 All Company News Deliver solutions using enabling technologies like AI enabled molecular design, high throughput screening, DNA-coded library, parallel synthesis. Explore Chemistry Most visited.

AI-assisted molecular designanalytical chemistryAPI manufacturingbioanalysiscomputational chemistryDMPKDNA-encoded library screeningdrug product manufacturingformulation developmenthigh throughput screeningin vivo modelsmedicinal chemistryparallel synthesispeptide chemistryprocess R&DScale upsynthetic chemistrytoxicology

Burleson Research Technologies (BRT) is a contract research organization specializing in immune safety, immunotoxicology, and preclinical efficacy research for pharmaceutical, biotechnology, chemical, and medical device organizations. Founded in 1996 by Drs. Gary and Florence Burleson, BRT provides customized preclinical research programs integrating in vivo, in vitro, ex vivo, and bioanalytical capabilities. The company operates an approximately 10,000-square-foot facility in Morrisville, North Carolina, near Research Triangle Park.

bioanalytical assayscell-based assayscustomized study designex vivo assessmentshost resistance modelshumanized and immunocompromised mouse modelshypersensitivity modelsimmunogenicity testingimmunotoxicity testingin vivo studiestumor models

Cellula BioPharma is developing a game changing CAR-T platform technology for solid tumors. The company is developing a Nucleotide Metabolic Reprogramed CAR (designated MR CAR), with efficacy and safety validated using in vitro assays and two different tumor mouse models. Their approach targets adenosine (ADO) inhibition, addressing nutrient starvation of T cells in solid tumors.

CAR-T cell therapy developmenttumor mouse models

ChemDiv is a fully integrated target-to-clinic contract research organization (CRO) that has worked for over 32 years on drug discovery programs for cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners. It offers integrated drug discovery services including custom chemistry, HTS, CADD, ADME, DMPK, discovery biology and preclinical services.

ADME/DMPK testinganimal modelscombinatorial chemistrycustom chemistryhigh throughput screening (HTS)in silico drug design (CADD)in vivo studieslibrary designmedicinal chemistrymolecular dockingmolecular dynamicspharmacokinetic studiestoxicology studiesvirtual screening

Cilcare is a biotech founded in 2014 dedicated to auditory sciences, supporting partners in the health and life-sciences sector in developing therapies to prevent and treat auditory-related diseases such as inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus. It offers ex vivo and in vivo pharmacological models, GLP toxicology for ototoxicity, and operates from France and the US.

behavioral testingbioanalysiscochlear implantationelectrophysiology (ABR, DPOAE)ex vivo cochlear explantsformulation for otic deliveryGLP toxicologyhistopathologyinner ear deliveryin vivo modelsmicrosurgerypharmacokinetics

Darya Pharmaceuticals is a client-focused, U.S.-based company providing comprehensive, end-to-end preclinical radiopharmaceutical research and development services, from small molecule and peptide preparation through in vivo assays and regulatory consultation.

biodistribution and dosimetrychemistry synthesisin vivo assaysnon-GLP pharm/tox studiesphage displayprotein expressionradiolabelingregulatory consultation